<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Exicure, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      David A. Giljohann
    • FOUNDED
      2009
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    dna ID, Inc.

    dna ID, Inc.

    The DNA ID platform is a community marketplace for genomics research. The app allo...

    The DNA ID platform is a community marketplace ...

    Amount Raised:    $57,589.00
    Fundraising Status:    EC
    Filing Type:    CF
    PRA Health Sciences, Inc.

    PRA Health Sciences, Inc.

    At PRA Health Sciences, we work side-by-side with our clients, to move drug discov...

    At PRA Health Sciences, we work side-by-side wi...

    Filing Type:    PU
    Astellas Pharma, Inc.

    Astellas Pharma, Inc.

    Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fiel...

    Astellas Pharma Inc. is a pharmaceutical compan...

    Filing Type:    PU
    Infinity Pharmaceuticals, Inc.

    Infinity Pharmaceuticals, Inc.

    Infinity Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicate...

    Infinity Pharmaceuticals, Inc. is an innovative...

    Filing Type:    PU
    Chiasma, Inc.

    Chiasma, Inc.

    Chiasma is focused on improving the lives of patients who face challenges associat...

    Chiasma is focused on improving the lives of pa...

    Filing Type:    PU
    BioCryst Pharmaceuticals, Inc.

    BioCryst Pharmaceuticals, Inc.

    BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...

    BioCryst Pharmaceuticals discovers novel, oral ...

    Filing Type:    PU
    Calithera Biosciences, Inc.

    Calithera Biosciences, Inc.

    Calithera is a clinical-stage biopharmaceutical company pioneering the discovery a...

    Calithera is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Turning Point Therapeutics, Inc.

    Turning Point Therapeutics, Inc.

    Turning Point Therapeutics is a clinical-stage precision oncology company with a p...

    Turning Point Therapeutics is a clinical-stage ...

    Filing Type:    PU
    Halozyme Therapeutics, Inc.

    Halozyme Therapeutics, Inc.

    Halozyme is a clinical-stage biotechnology company focused on developing and comme...

    Halozyme is a clinical-stage biotechnology comp...

    Filing Type:    PU
    Apellis Pharmaceuticals, Inc.

    Apellis Pharmaceuticals, Inc.

    We are a clinical-stage biopharmaceutical company focused on the development of no...

    We are a clinical-stage biopharmaceutical compa...

    Filing Type:    PU
    ChemoCentryx, Inc.

    ChemoCentryx, Inc.

    ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...

    ChemoCentryx is a biopharmaceutical company foc...

    Filing Type:    PU
    Arena Pharmaceuticals, Inc.

    Arena Pharmaceuticals, Inc.

    Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...

    Arena Pharmaceuticals is driven to deliver nove...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.